Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) has provided an announcement.
Race Oncology Ltd has reported significant progress in its Q4 FY2025 activities, notably the successful and safe treatment of the first patient with their drug RC220, both alone and in combination with doxorubicin, in a Phase 1 trial for advanced solid tumors. The company has also strengthened its clinical leadership team with new appointments and has managed its capital prudently, maintaining a strong cash position of $13.67 million. These developments position Race well for continued operations and growth through CY2026, with further trials approved in Hong Kong hospitals.
More about Race Oncology Ltd.
Race Oncology Ltd is a pharmaceutical company focused on the development of cancer therapies. The company is engaged in research and development, particularly in the field of cardioprotection and anticancer treatments, with a market focus on advanced solid tumors.
Average Trading Volume: 110,686
Technical Sentiment Signal: Sell
Current Market Cap: A$199.8M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.